LENZ Therapeutics

LENZ · NASDAQ

$3.19−$0.11 (−3.33%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $3.30

LENZ analyst rating

BuyConsensus of 5 analysts over the last 12 months. 80% rate it a buy.

Strong buy0
Buy4
Hold1
Underperform0
Sell0

12-month price target · 8 analysts

Average $22.44 (+603.4% upside)

Low: $7.07
Now: $3.19
High: $63.00

Upgrades and downgrades

The latest rating actions, newest first

LENZ analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Piper Sandler	Oct 19, 2026	Maintains	Neutral	$7.00 → $5.00	40%
Piper Sandler	Aug 12, 2026	Maintains	Neutral	$12.00 → $7.00	40%
HC Wainwright & Co.	Jul 7, 2026	Maintains	Buy	$38.00	47%
Citigroup	May 13, 2026	Maintains	Buy	$26.00 → $20.00	42%
HC Wainwright & Co.	May 12, 2026	Maintains	Buy	$48.00 → $38.00	47%
Piper Sandler	May 12, 2026	Downgrade	Overweight → Neutral	$39.00 → $12.00	40%
HC Wainwright & Co.	Apr 21, 2026	Maintains	Buy	$56.00 → $48.00	47%
Citigroup	Mar 26, 2026	Maintains	Buy	$52.00 → $26.00	42%
B of A Securities	Mar 25, 2026	Maintains	Buy	$35.00 → $29.00	56%
Raymond James	Oct 20, 2025	Maintains	Outperform	$40.00 → $50.00	57%

The case for and against

Updated Oct 15, 2026

Bull case

LENZ Therapeutics is viewed positively because VIZZ combines a differentiated aceclidine, pupil-selective mechanism with up to 10 hours of durability, a tolerability profile that appears superior to pilocarpine-based alternatives, and real-world prescription momentum that reached approximately 46K filled prescriptions across over 10K unique ECP prescribers through 1Q26. The launch is being amplified by a DTC campaign, a telehealth prescribing channel, and an expanding sales force from 88 to 117 territories, all of which should improve access and deepen adoption over the coming quarters. Additional upside comes from ex-US expansion through partnerships in Australia, New Zealand, and Greater China, where the NDA has been submitted and approval is anticipated in 1Q27.

Bear case

LENZ Therapeutics is facing a negative outlook because even after the telehealth launch and national TV campaign, the company still had to rely on new commercial tactics to address slower-than-expected ECP integration and access barriers, signaling that organic demand has been weaker than hoped. Although weekly Symphony prescriptions by mail-order rose 94% to 1,427 from 736 and July volumes improved, the analyst still lowered peak U.S. VIZZ revenue estimates to $165.4M from $268.8M, implying a much smaller commercialization opportunity than initially expected. The company’s $220.0M cash balance and reduced SG&A to $39.4M help near-term liquidity, but the $1.02 EPS loss, restructuring and impairment costs, and explicit risks around capital needs and commercialization keep the fundamental profile fragile.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.